Skip to main content
. 2019 Nov 12;11(11):600. doi: 10.3390/pharmaceutics11110600

Figure 4.

Figure 4

(A) Evaluation of luciferase knockdown efficacies of P5Y/siRNA complexes for in vivo use, in stably expressing HCT116-Luc cells over a range of different siRNA concentrations as indicated in the figure. (B) Luciferase activity of lysed HCT116-Luc tumors after in vivo treatment with P5Y/siRNA complexes. Bars represent the luciferase activities normalized for total protein concentrations from individual tumors of siCtrl-treated (blue) and siLuc-treated (red) mice.